FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy

Table 3 Putative biomarkers of efficacy and/or toxicity of irinotecan in colorectal cancer

Gene	Transcript	Protein	SNP	Effect	Ref.
ABCB1	-	-	rs11288503	Decreased clearance of irinotecan	Mathijssen et al[103] 2003
ABCB1	-	-	rs112503T-rs2032582T-rs1045642T haplotype	Higher levels of SN-38	Sai et al[104] 2010
	-	-	rs112503T-rs2032582T-rs1045642T haplotype	Shorter OS	Glimelius et al[106] 2010
ABCG2	-	-	rs7699188	Associate with RR	De Mattia et al[105] 2013
	-	-	GG genotype in rs425215	Higher GI toxicity	Di Martino et al[117] 2011
ABCC2	-	-	CC genotype in rs717620	Longer PFS	Akiyama et al[109] 2012
	-	-	CC genotype in rs562	Higher GI toxicity	Di Martino et al[117] 2011
SLCO1B1	-	-	GA/AA genotype in rs2306283	Higher RR	Huang et al[110] 2013
	-	-	GA genotype in rs 2306283	Lower GI toxicity	Di Martino et al[117] 2011
SLC19A1	-	-	GG genotype in rs1051266	Higher RR	Huang et al[82] 2013
UGT1A1	-	-	28 allele in rs81753471	No association with RR	Dias et al[115] 2012
	-	-	28 allele in rs81753471	Lower RR	Marcuello et al[114] 2011
	-	-	28 allele in rs81753471	Reduced activity of UGT1A1	Swen et al[62] 2011
	-	-	28 allele in rs81753471	Increased toxicity, dose reduction recommended	Swen et al[62] 2011

¹Due to lower tolerated dose. PFS: Progression-free survival; RR: Response rate; OS: Overall survival; GI: Gastrointestinal.